Cyclosporine is an immunosuppressant drug used in organ transplants or for the treatment of autoimmune diseases. We developed and validated a simple, sensitive, and specific method using UPLC-MS/MS to determine cyclosporine levels in human whole blood. MS/MS detection was performed in the positive electrospray ionization mode with multiple reaction monitoring. Cyclosporine was extracted from whole-blood samples using ascomycin as an internal standard. The mass transitions m/z 1203.49 → 1185.53 and m/z 814.71 → 796.67 were used to assay the analyte and IS. This method was validated with respect to linearity, specificity, accuracy, precision, recovery, and stability. The method exhibited a linear response from 10 to 1000 ng mL -1 with correlation coefficient values >0.99. The precision and the accuracy values were within 15%, except at the lower limit of quatification (LLOQ). Cyclosporine was stable in whole blood with no evidence of degradation. This method was successfully applied to a pharmacokinetic study of cyclosporine in healthy volunteers following oral administration.
Introduction
Cyclosporine and cyclosporine A are effective immunosuppressive drugs used in organ transplants or for the treatment of autoimmune diseases. 1 Cyclosporine inhibits cytokines, particularly interleukin 2 and gamma interferon, which are secreted when transplanted organs are rejected by T-lymphocytes. 2 Therefore, immunosuppressants reduce the activity of the immune system and the risk of organ rejection.
The structure of cyclosporine (C62H111N11O12) is shown in Fig. 1 . Cyclosporine analyses are difficult because of its relatively high molecular weight (1202.61 Daltons). Most analytical methods used for cyclosporine require whole blood, in which the majority of cyclosporine is associated with erythrocytes. When whole-blood samples are cooled to room temperature, cyclosporine concentrations in erythrocytes increase, while the plasma cyclosporine concentration decreases.
Thus, whole-blood measurements of cyclosporine are recommended. 3 Cyclosporine requires careful drug monitoring due to its narrow therapeutic index and high inter-individual pharmacokinetic variability. The analytical methods used for therapeutic drug monitoring (TDM) must be accurate and highly reproducible. The chromatographic techniques, such as HPLC and LC-MS/MS, offer higher sensitivity, and boast both high accuracy and specificity. Many studies have been addressed specificity with regard to measurements of cyclosporine levels. [4] [5] [6] [7] [8] Recent studies have analyzed cyclosporine using HPLC-MS/ MS. [9] [10] [11] [12] Also, some reports have been published on the simultaneous analysis of several immunosuppressant drugs (sirolimus, everolimus, and tacrolimus) [13] [14] [15] [16] [17] or the simultaneous analysis of cyclosporine metabolites. [18] [19] [20] [21] These studies are time-consuming, and require many steps for sample preparation, including evaporation or reconstitution. [9] [10] [11] [12] 16, 17 UPLC-MS/MS has been used as an alternative to traditional HPLC, and has revolutionized the analysis of biological samples. UPLC provides increased resolution and sensitivity, reduced analysis time, and a lower cost per assay than HPLC. 11, 22, 23, 37 UPLC has superior resolution, sensitivity and sample throughput compared to HPLC, based on a pharmacokinetic and metabolism study. 24 However, limited data are available concerning analyses of cyclosporine in whole-blood samples by UPLC-MS/MS.
In this study, we developed a rapid and simple method for the quantitative determination of cyclosporine in human whole blood using UPLC-MS/MS. We applied this method to a pharmacokinetic study of cyclosporine in healthy volunteers after oral administration.
Experimental

Chemicals and reagents
Cyclosporine and the internal standard (IS) ascomycin were purchased from Sigma-Aldrich (St. Louis, MO). 13, 36 HPLCgrade acetonitrile and methanol were purchased from Merck (Darmstadt, Germany).
Formic acid and zinc sulfate heptahydrate were obtained from Sigma-Aldrich. Water was deionized and purified on a Milli-Q water purification system from Millipore (Bedford, MA). All solvents were passed through a 0.22-μm membrane filter, and degassed prior to use. Blank human whole blood treated with heparin (an anticoagulant) was used to prepare and calibrate quality control (QC) samples.
Preparation of standards and QC samples
Stock solutions of cyclosporine and the IS were prepared at concentrations of 1 mg mL -1 and 100 μg mL -1 , respectively. 16 Standard working solutions of cyclosporine at concentrations of 100, 200, 500, 1000, 2000, 5000, and 10000 ng mL -1 , and a 10000 ng mL -1 solution of the IS, were prepared by serial dilution of stock solutions. The diluent consisted of a mixture of 0.1% formic acid in water and 0.1% formic acid in acetonitrile (50/50, v/v). Blank whole blood was spiked with standard working solutions of cyclosporine to achieve final concentrations of 10, 20, 50, 100, 200, 500, and 1000 ng mL -1 . QC samples of cyclosporine were prepared in a similar manner with concentrations of 10 ng mL -1 (lower limit of quantification, LLOQ), 20 ng mL -1 (low, LQC), 200 ng mL -1 (middle, MQC), and 800 ng mL -1 (high, HQC). Standard working solutions and QC samples were made daily prior to analysis. All stock solutions were stored at -20 C.
Whole-blood sample preparation
Human whole-blood samples were stored at -70 C and thawed gradually to room temperature before processing. After transferring 200-μL aliquots of whole blood into 1.7-mL clear tubes, 10 μL of the IS (10000 ng mL -1 ) was added. Next, 50 μL of 0.1 M zinc sulfate buffer and 540 μL of acetonitrile were added to each tube, and the mixture was vortexed for 5 min and centrifuged at 13200 rpm for 5 min at 4 C. The supernatant (150 μL) was then transferred to a 0.22-μm nylon filter tube and centrifuged at 13200 rpm for 2 min at 4 C. The filtered solution was transferred into a vial, and 5 μL of this solution was injected into the UPLC-MS/MS system for analysis.
Liquid chromatography conditions
Analytical separations were performed with an ACQUITY TM UPLC system (Waters Corp., Milford, MA) that included a binary pump, a micro vacuum degasser, a thermostatted autosampler, and a thermostatted column compartment. The UPLC column was an ACQUITY TM UPLC BEH C18 column (100 mm × 2.1 mm, 1.7 μm) 19 maintained at 50 C. Mobile phase A consisted of distilled water containing 0.1% formic acid, while mobile phase B consisted of acetonitrile containing 0.1% formic acid. The LC system was operated in the gradient mode so as to deliver the mobile phase at a flow rate of 0.35 mL min -1 . We initially delivered 80% mobile-phase A/20% mobile-phase B for 3 min. Next, mobile-phase B was increased from 20 to 95%, maintained at 95% for 1 min, and followed by a rapid decrease back to 20%, which was held for 2 min. The total run time was 6 min, and the data-acquisition run time was maintained at 5 min for the mass spectrometer. The mobile phases were filtered through 0.22 μm membrane filters and degassed before use. The autosampler temperature was kept at 10 C and the sample injection volume was 5 μL. System control, data acquisition, and processing were performed using MassLynx TM software with QuanLynx TM (Waters Corp.).
Mass spectrometry conditions
Mass spectrometric detection was performed on a Quattro Premier XE TM tandem triple quadrupole mass spectrometer (Waters Corp.) in the positive electrospray ionization mode. Nitrogen was used for desolvation (800 L h -1 ) and as a cone gas (50 L h -1 ). Argon was used as the collision gas. The optimal MS parameters were as follows: capillary voltage of 4. 
Method validation
The method was validated with regard to the calibration curve, linearity, specificity, accuracy, precision, recovery, and stability according to the Food and Drug Administration (FDA) guidelines for bioanalytical method validation. 36, 37 Calibration curves and linearity. Calibration curves were acquired by plotting the cyclosporine:IS peak area ratio versus the nominal concentration of the calibration standards. The standards used to generate the calibration curves contained 10, 20, 50, 100, 200, 500, or 1000 ng mL -1 of cyclosporine and 10000 ng mL -1 of IS. The calibration curves were fitted by a weighted (1/x 2 ) least-squares regression to determine the linearity. Calibration curves were constructed and applied daily during method validation. Specificity. The specificity was evaluated by comparing chromatograms of drug-free whole blood from six individuals with blank plasma spiked with cyclosporine at LLOQ (10 ng mL -1 ) and the IS (10000 ng mL -1 ). Accuracy and precision. The intra-day accuracy and precision were determined by analyzing replicate QC samples (n = 5) of four different concentrations (10, 20, 200 , and 800 ng mL -1 ) on the same day. The inter-day accuracy and precision were estimated by replicate analyses (n = 5) of the same QC samples on five different days. The accuracy, expressed as the percent deviation (% DEV), was calculated as [(mean measured concentration -nominal concentration)/nominal concentration] × 100. The precision, expressed as the relative standard deviation (RSD), was calculated as (SD/mean measured concentration) × 100. The criteria for the acceptable QC sample accuracy was within ±15% from the nominal concentrations, while the acceptable precision was less than 15% of the relative standard deviation (RSD), except at the LLOQ. LLOQ samples should not exceed 20% of the coefficient of variation (CV). Extraction recovery. The cyclosporine extraction recovery was determined based on the detector response obtained from pre-extracted, whole-blood samples compared to the detector response obtained for the nominal concentration of the pure authentic standard at three concentrations (20, 200 , and 800 ng mL -1 ) of QC samples (n = 3). The recovery of the IS was determined based on a single concentration of 10000 ng mL -1 in the same manner. Stability. The stability of cyclosporine was assessed under four different conditions: the short-term temperature stability at room temperature for 4 h, the long-term temperature stability at -70 C for at least 1 month, the post-preparative stability at 10 C for 24 h in an autosampler, and the freeze-thaw stability for three cycles. The stability of cyclosporine was analyzed at low (20 ng mL -1 ) and high (800 ng mL -1 ) concentrations of wholeblood QC samples in triplicate, and compared to freshly prepared QC samples at the same concentrations.
Pharmacokinetic application
This method was applied to a pharmacokinetic study to determine the whole-blood concentrations of cyclosporine after a single oral dose. The study protocol was approved by the institutional review board of Kyungpook National University Hospital, Daegu, Korea. Before participating in the study, eight healthy male volunteers gave their written consent, and the studies were carried out in compliance with the Declaration of Helsinki and its amendments, following good clinical practice (GCP) guidelines. During the study, all volunteers were hospitalized, and the use of other medication was prohibited. To determine the whole-blood concentrations of cyclosporine, serial blood samples (10 mL) were collected in sodium heparinized tubes before (predose) and at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, and 24 h after a single 100-mg dose of cyclosporine. All whole-blood samples were stored frozen at -70 C until analysis.
Pharmacokinetic parameters were estimated from whole-blood concentrations using WinNonlin 5.2 software (Pharsight, Mountain View, CA) with a noncompartmental model. The values calculated were the maximum whole-blood concentration (Cmax) at the respective time (Tmax) and area under the whole-blood concentration-time curve from 0 to 24 h (AUC0-24).
Results and Discussion
Method development
The parent-to-daughter ion pairs were m/z 1203.49 → 1185.53 for cyclosporine and 814.71 → 796.67 for the IS. Therefore, the corresponding transitions associated with these peaks were selected for MRM analysis. Formic acid in water (0.1%) and 0.1% formic acid in acetonitrile were used as mobile phases in the gradient mode to separate sample peaks. The infusion of the mobile phase with analyte was critical in optimizing the desolvation and cone gas flows, both of which depend on the flow rate.
Kovarik et al. 25 used RIA to measure the levels of sandimmune following the administration of capsules containing 180 mg of the drug. A micro-emulsion of cyclosporine A (Neoral ® ) was analyzed using LC-MS/MS after the administration of a 180-mg Neoral solution. 26 However, no attempts have been made to use LC-MS/MS to determine the pharmacokinetic parameters of 100-mg sandimmune capsules. HPLC-UV analyses were used by Kees et al. 27 after the administration of a 200-mg Neoral capsule, and also by Chang et al. 28 after the administration of a 700-mg sandimmune solution. Compared to these HPLC-UV methods, the UPLC-MS/MS described herein was faster and offered more flexibility with regard to the mobile phase because of less matrix interferences. UPLC-MS/MS is generally considered to be more appropriate for TDM measurements, since the more recent therapeutic ranges of immunosuppressants are sometimes lower than the lower limits of detection (LODs) of the HPLC-UV methods. In addition, UPLC-MS/MS is designed in a special way to withstand high system back-pressures. 29 
Sample preparation
This study details the optimization of a sample preparation method based on protein precipitation. Acetonitrile was used as the extracting solvent to reduce chromatographic interference. This procedure was much simpler than that used in previous studies. [9] [10] [11] [12] 16, 17 and resulted in acceptable extraction recovery and precision for both cyclosporine and the IS.
Whitman et al. 30 measured the levels of cyclosporine A (CsA) and its metabolites in renal biopsy tissues by HPLC electrospraymass spectrometry in the single ion-monitoring mode. Taylor et al. 9 showed that HPLC-MS/MS could be used to measure the CsA levels at clinically relevant concentrations using minimal volumes of whole blood (50 μL). However, both of these methods had analysis times >10 min per sample. Thus, the throughput limitation of these methods makes them unsuitable for TDM.
McMahon et al. 31 analyzed CsA using LC-MS along with a semi-automated, 96-well, solid-phase extraction system. In this experiment, 350 μL of whole blood was pretreated and extracted by SPE. Salm et al. 10 and Koal et al. 16 analyzed cyclosporine in lower volumes of blood (50 μL) using HPLC-MS. However, their sample pretreatment and SPE processes were time consuming and a high flow rate was used for the LC system. Christians et al. 17 developed a sample pretreatment process, including an evaporation step and a procedure for adding solvents, such as dichloromethane, for an LC-MS method to analyze cyclosporine. This method was considerably more complicated than the method described herein. The HPLC-MS methods of Hebert et al. 12 and Tszyrsznic et al. 32 were relatively simple, but the amount of whole blood required for each sample pretreatment was relatively large. The process developed in the current study not only uses less whole blood during pretreatment, but is also faster and simpler, owing to direct injection. It is also highly reproducible, and does not involve an SPE, sample evaporation, or reconstitution phases. The present technique was demonstrably applicable to pharmacokinetic studies based on quantitative analyses of cyclosporine in human whole-blood samples, and is suitable for use in TDM. It is expected that the use of our method should reduce the incidence of adverse, drugrelated events as well as the mortality rates and hospitalization periods, thereby improving the quality of patient treatment and reducing the overall medical costs.
Method validation
Specificity. Typical chromatograms of cyclosporine and the IS from blank whole blood and whole blood spiked with cyclosporine at LLOQ (10 ng mL -1 ) and 10000 ng mL -1 of IS are shown in Fig. 3 . Each peak was distinct, and no significant interference peaks were detected for cyclosporine or the IS. Calibration curves and linearity. The calibration curves were linear over the concentration range of 10 -1000 ng mL -1 for cyclosporine in human whole-blood samples. The correlation coefficients (r 2 ) of the calibration curves were over 0.99. Accuracy and precision. The intra-day and inter-day accuracy and precision data are summarized in Table 1 . The intra-day accuracy for cyclosporine ranged from 88.5 to 100.4%, and the inter-day accuracy ranged from 90.0 to 98.6%. Intra-and interday accuracy of LLOQ samples were 80.8 and 100.0%, respectively. The intra-day precision ranged from 2.1 to 9.1%, and the inter-day precision ranged from 6.7 to 13.6%. The intra-and inter-day precision at the LLOQ were 16.1 and 15.4%, respectively. The accuracy of all QC samples was within 15%, and the precision of the QC samples was also less than 15%. LLOQ samples also satisfied the accuracy and precision conditions. Recovery. Recovery data are presented in Table 2 . The mean percent recovery values of cyclosporine at 20, 200, and 800 ng mL -1 were 37.0, 36.8, and 33.1%, respectively. For the IS, the mean percent recovery at 10000 ng mL -1 was 34.6%. Although these values were low, the RSD percent of each concentration of cyclosporine and the IS were within 15%. Stability. Table 2 gives the summarized results of the Fig. 3 Typical chromatograms of cyclosporine (upper panel) and ascomycin (lower panel) in human whole-blood samples obtained from (a) a drug-free blank whole-blood sample and (b) a whole-blood sample spiked with cyclosporine at LLOQ (10 ng mL -1 ) with 10000 ng mL -1 ascomycin. Table 1 Intra-day (n = 5) and inter-day (n = 5) accuracy and precision of quality control samples containing cyclosporine at four concentrations (10, 20, 200 , and 800 ng mL -1 ) in whole blood cyclosporine and IS stability data. No significant differences between the QC samples of cyclosporine and the IS were observed after storage at room temperature for 4 h. Cyclosporine and the IS were stable in an autosampler at 10 C for 24 h. They were also stable over three freeze-thaw cycles. QC samples stored in a freezer below -70 C were stable for at least 1 month. The stock solution of cyclosporine and the IS stored at -20 C remained stable for at least 3 months.
Pharmacokinetic applications
The methods described above were applied to a pharmacokinetic analysis to determine the whole-blood concentration of cyclosporine after a single oral dose. Eight healthy male volunteers were administered 100 mg of cyclosporine, and whole-blood samples were collected for up to 24 h after oral administration. The resulting mean whole-blood concentration-time curve is shown in Fig. 4 . In this study, the maximum whole-blood concentration (Cmax) and the area under the concentration-time curve (AUC0-24) were 957.10 ± 234.79 ng mL -1 at 1.5 ± 0.46 h (Tmax) and 2362.16 ± 430.76 h ng mL -1 , respectively. These pharmacokinetic parameters were in agreement with previous reports.
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Conclusions
A selective, accurate, and precise UPLC-MS/MS method was developed for the quantitative determination of cyclosporine in human whole blood. This UPLC-MS/MS method was validated for specificity, linearity, accuracy, precision, recovery, and stability, and was successfully applied to a pharmacokinetic study for the analysis of cyclosporine in human whole-blood samples.
